Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Superior efficacy of triple-antigen hepatitis B vaccine confirmed in inadequate responders

Dec. 27, 2001

Bay-41-4109 characterized at ICAAC as a novel, promising anti-HBV agent

Dec. 20, 2001

Initiation of phase II trial of Ceplene in triple-drug combination therapy

Dec. 20, 2001

Cangene seeks approval for antihepatitis B hyperimmune in Canada

Dec. 20, 2001

Novel macrocyclic compounds under development for use in HCV infection

Dec. 19, 2001

Good progression reported in phase II trial of COLAL-PRED in ulcerative colitis

Dec. 19, 2001

XTL Biopharmaceuticals extends human lactoferrin research program with AM-Pharma

Dec. 19, 2001

Tularik discovers new series of HCV polymerase inhibitors

Dec. 14, 2001

Wide series of macrocyclic compounds for HCV designed and disclosed in recent patent

Dec. 13, 2001

Synsorb discontinues Synsorb-Cd development program

Dec. 13, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...